• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form PRE 14A filed by Solid Biosciences Inc.

    4/11/25 5:03:57 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLDB alert in real time by email
    ����JFIFyy��Ńhttp://ns.adobe.com/xap/1.0/ application/postscript g01a01 File Name: g01a01.ai Username: Delta Local Time: 26-Jan-2023 04:32:00 EST Time: 25-Jan-2023 19:02:00 Script Version: 2.6 Illustrator Version: 26.5.2 Graphic type: Artwork ***The preflight check is complete. Please ensure manual checks are completed per process.*** The following colors are present in the document: CMYK Black --------------------------------------------------------------------------------------------- 2023-01-26T04:32:05+05:30 2023-01-26T04:32:05+05:30 2023-01-26T04:32:05+05:30 Adobe Illustrator 26.5 (Windows) 256 80 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAUAEAAwER AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAAAAAQFAwIGAQAHCAkKCwEAAgIDAQEBAQEAAAAAAAAA AQACAwQFBgcICQoLEAACAQMDAgQCBgcDBAIGAnMBAgMRBAAFIRIxQVEGE2EicYEUMpGhBxWxQiPB UtHhMxZi8CRygvElQzRTkqKyY3PCNUQnk6OzNhdUZHTD0uIIJoMJChgZhJRFRqS0VtNVKBry4/PE 1OT0ZXWFlaW1xdXl9WZ2hpamtsbW5vY3R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo+Ck5SVlpeYmZ qbnJ2en5KjpKWmp6ipqqusra6voRAAICAQIDBQUEBQYECAMDbQEAAhEDBCESMUEFURNhIgZxgZEy obHwFMHR4SNCFVJicvEzJDRDghaSUyWiY7LCB3PSNeJEgxdUkwgJChgZJjZFGidkdFU38qOzwygp 0+PzhJSktMTU5PRldYWVpbXF1eX1RlZmdoaWprbG1ub2R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo +DlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+v/aAAwDAQACEQMRAD8A9U4q4kKCSaAbknoBirBP Mn5q6dYu1tpKC+uF2ackiBT7Ebv9FB75rNR2lGO0Nz9jvdH2HOfqyekd3X9iB03SvPPmqzjv7vWv qNjcVMcUAIJUEjdE9MUqP2mOV48WbOOIyqJb82fS6WRhHHxSHf8Ag/cjY/yh0dviu7+7mkPV1KLU /wCyWTLB2XDqS0nt/J/DGI+f7Fr/AJS2kJL6dqt1aydmbix/4T0sB7MA+mRH4+Cjt2R+uEZfjztL dU1Pz15MaFru+j1OymYrH6vJ2JG5qTRwaf5RGU5MmfT1Z4gXJwYdLrL4YmEh3fivsZR5X/MHRtcK 27H6nqDbfVpDUMf+K32DfLY5m6fXQybcpOs1vZWTBv8AVDv/AFsozNdW7FXYq7FXYq7FXYq7FXYq 7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXYq7FXEhQSTQDck9AMVeb6rquredNWfRdFcw6JCaXl4O jjuSe4P7K9+p9tRkyS1EuCH0dS9HgwY9Hj8XLvkPIfj7T0UG/LHy6msLZProEjUYWJCCcjrTly6k dPgyP8n4+Ph4/h1bB21mOPi8P/O3r8fF6TZ2lvZ2kVpbII4IECRoOwUUzbwgIgAcg83kyGcjKXMs X82fmNY6De/UY7Zry7UBplDiNU5CoBajmtN+mYWp18cUuGrLtND2RPPHjJ4Y/NSTzfdeY/LF++gI 0GsQBQbclSwDNuUJoDVQae+R/NHLjPBtMMjoI6fPEZt8Z6/rUtG8u6tr3lN7LzT6i3HrF7OV6eug CgAn6Swo29PowYsEsuKsnO9u9lqNXjwajiwVVb9yXr+TcaRSsuqM1yBW2Ii9NVcGo5fE5I+VMq/k rb6t3JPtASR6Nuu9pj5N816gl83lvzCDHqkPw28zf7tAHRm7tTdW/a+fW3S6mQl4eT6nG7Q0MDHx sP0Hn5fj7Gb5snSOxV2KuxV2KuxV2KuxV2KuxV2KuxV2KuxV2KuxV2KuxV2KuxV2KuxV2KsK/MnW bpYLby/p9Wv9VIRgpoRETxp/szt8gc12vymhjj9Unddj6eJJzT+iH3/s/UyHy3oFroelRWMABZRy nlpQySH7TH+HtmVp8Axx4Q6/WaqWfIZH4eQYzdeVtBk88pqbazElz6yTHTi6eqZU40WpflQkdOPt mHLTw8bi4hd8nZQ1uUaXg8M1VcXSvkmXmvz7ZeXb+3s5baSd5UEsjKQvFCSoIr9o1U7bZdqdaMUg Ktx9D2XLUQMgQK2YX5+8n6zPrUmq6fbyXlpfBJB6SlnRuABDKPi7VG2a/WaWZnxRFiTuey+0MccQ xzIjKPej/J+n3flDRtR8wavA6FlSOG02DkFqVbrxqxHXLNLA4IHJMfBo7Qyx1eSOHGfizLyv5qtN e0qS/WM2ohcxzpIwIUqA1eewpQ5sNPqRljxcqdPrdDLBkEL4r5JhZavpV8zLZXkFyyfbWGRXIHSp Ck5bDLGXIguNkwZIfVEx94Y5+Ynls6hpv6TswU1TTh6sUibMyJ8RXbuv2l/tzE12n4o8Q+qLsuyd Z4c+CX0T2TPyd5gGu6FBeMR9ZX91dKNqSr1NP8oUb6cu0ufxIA9eri9oaXwMpj05j3J3mS4S2SRI 42kkYJGgLOxNAABUknFXhPnb869YvLuW08uyfUtPQlRdhQZpaftDlXgvhQV9+2FDBJfN3muWT1JN ZvmfsTcy7d9vi2xVP/Lv5uectInUzXbana1HqW94TISP8mU/Gp+kj2xV795X8y6b5j0eLVLBj6Ul Vkjb7cci/aRvcV+7fAlMbu7tbO1lurqVYbaFS8srmiqo6knFXh/nH88dVup5LXy4PqVmpKi8dQ08 nuoaqoPor8umFDAZvNvmmeQyS6xeu57m4l/5qxVNNE/M/wA7aRKrR6lJdRCgNvdkzoQO3xnkv+xY Yq9x8g/mNpfmy2MYX6rqkK1uLNjWo/njP7S/iPxISyTVppIdLvJom4yRwSOjeDKhIOKvmv8A5Wr+ YH/V5l/4CL/mjCh9KaTNJNpdnNK3KSSCN3bxZkBJwJRWKsE/OPzBrGh+WLW70m5a1uHvY4nkUKSU MUrFfiDDqoxVgn5Z/mB5w1bzvpun6hqT3FnN63qwssYDcLeR13VQdmUHCr1T8xNTvtM8manf2Epg u4EQxSgAlSZVU7EEdDgV4H/ytX8wP+rzL/wEX/NGFC6P82PzCRgy6w5I/mihYfcyEYqyTQfz68wW 0iprNtFf29fikiHozAe1KoflxHzxpXsvl3zJpHmHTU1DS5vVgb4XU7PG46o69iP9rbAliPltf01+ Ymraq/xw6bWC38A28akfMK5+nNVp/wB5qJS6R/seg1h8HRwxjnPc/f8AqZprj3aaLfvZ1+trbymD j15hDxp716ZsMxIga506bTCJyxEvp4hb50LMzFiSWJqSetc5V9Dp7loOj2mr+XtIudbtEub2KFSs ky1bj+zyr1qtDvnRYMQyY4mYs08RqtRLFmnHFLhiT0ZNma6xSurW2u7d7a5iWaCUcZI3FVI+RyMo iQo8mUJygRKJohgX5mWS6X5Wt7PS4Bbae9x/pKRCgJ4krzPepHfwGaztCHBjAiKjbv8AsbJ4ucyy G58O1vPvKst7H5j05rIn6wZ41UDuGajA+3GtfbNXpyRkHDzt3+ujE4ZcXKi99S9spLh7VLiJ7lBW SAOpdR7rWozpxOJNXu8EccgOIg13sE8nr+hfPWsaEPhtZx69unYUo6gf7CQj6M1ml/d55Q6F3vaB 8bSwy/xDY/j3h6Dm1efYx+ZtxNb+QtZkhJDmD0yR/LI6o/8AwrHFXzv5MTRX80aautlRpZlH1jns nQ8eZ/l505e2FD6os4bBbNI7NIhZlaRpCFEXEinwhfhpgS8q/M38pJ9Qvre/8r2Uayy8xfwq6RR1 FODqrFQCd60wqmX5P+UfNflp9Sh1eBYbS5EbwhZUkHqJyDbKTSqkfdirH/z581zNdW/lq3crCirc X1D9pmP7tD7KBy+keGIVv8rPynsb2wi17zBEZY5/isrFqhCnaSSm55dVHSm5rXFXr0Wj6TDD6MVl bxw0p6SRIq0P+SBTArz/APML8odK1KxlvtBtks9ViBf6vEOEU4AqU4D4Vc9iO/XxBV4fo+rX+i6r b6jZsYru0kDLWo6bMrDwYbEYofUT6nBqvlCTUrfaG8sXmQdSOcRPE+46HAl8n4UPrzRP+OLp/wDz DQ/8mxgSjcVeafn9/wAodZ/9tGP/AJMTYQrzP8nv/JjaR/0cf9QsuKHtf5rf+S+1j/jHH/yeTAEv nfynbwXPmnRre4RZYJr62jliYVVkeZQykeBBwofSUn5d+RpEKNoloAwoSsYU/QVoRgS8m/NP8q7b y/bfpnReZ03mEubZyWMJbZWVjuUJ233B/AoSD8rvNM+gea7WrkWN86214nbi5or/ADRjX5VxVmv5 ceaLix10WUih7fVJQspp8YkaoVgfCp3Gc9oNQYzrpJ7PtfRCeLiHOA+x7LnQPGsAurv8v185Lp0u lBr5pVjNxxHo+s9CAU5UO5oTx6/fmrlLB43Dw738Ld/DHq/y3GJ+muXWvf8AtZ/m0dA7FXYqh9RW yawuPrqLJaCNmnRxyUooqaj6MhkrhPFybMJlxjh2lezEPId95Nvr25Oj6YbO7hHLnJ8TGNjSqks/ H3GYGinhlI8EaLt+1MephEeJPiifvbsvI36I8y3XmSW9MltH69wIQp9Q81YsGNd6V+nGOj8PIchO 25XJ2l42AYRGpGh5MS8ueYr3WPzGstRnVUeQvGsaCgEfpOAD3JFepzCwZzPUCRdtq9JHDo5QHT77 D2PN+8chtT0621LTrnT7peVvdRtFKO/FxTb38MVfNnmz8svNHl+4lJtXvNPUn0r2BS6lexdVqUPj XbwJwoSDTdd1rS25adf3Foa1IhkZAfmAaH6cVZho/wCdfnaxZBdTRajCuzJOgDEezx8DX3NcVez+ SPPelebbB57VTBdQEC6s3ILIW6EEfaU9jTAl4L+aMkkv5g6wZvhImRK9aKsaqp/4EYUPpq2git7e KCEcYYkVI1HQKooB92BKpirsVfKvn63gt/OmtRQACIXcpAHQFm5MB8icKHtP5cyyyflHH6g+zb3q ofFRJLT7umKXzvih9eaJ/wAcXT/+YaH/AJNjAlG4q80/P7/lDrP/ALaMf/JibCFeZ/k9/wCTG0j/ AKOP+oWXFD2v81v/ACX2sf8AGOP/AJPJgCXz35L/AOUx0H/to2n/ACfTCh9YYEpF57hil8la6soB UWNw4B/mSMsv/DAYq+VFZlYMpowNQR2Iwoe3fln5YguNauby4kPqaRKFFvTq55BWY/5JU7eOaHs/ TiUyT/C9b2zrTHEIgf3g5sg8q+YPONz5jvbfV4DFp0KyM5eP00h4n4aSUHKo8TuN8ytNnynIRMen 7nX67SaaOGJxm5mut38Px3IGfzn+XbeYxqDWMsl0jADUQvwVFAH4cwTQDrxrlctVp/E4qN97fHs7 WeDwcQ4f5v6Lr9NPRYJ4p4Y54XEkUqh43XcMrCoIzbRIIsPPSiYkg8wvwsXYqgNc1fTdJ06S71Fu NuPgK05Fy37CjuTlWbLGEblyb9Np55ZiMObEfJfmfyN+kHs9Ls3065uzRWl3EhG4UNzfifBemYOk 1GHiqI4SXb9o6LVcHFklxiPd0+wM7kjSSNo3HJHBVlPcEUIzZEWKdECQbDyrSfLUGk/mfa2FtM00 MQaerD4kBiYhWp17b5pMeAQ1IiD+Keqz6w5dCZyFE7faHq+bx5RJfOPmVfLWgT6u1s10kDIrRK3A /vHCV5Ub+bFWIeVvzqsNd1610ltOazN2WRJ3mDgMFLKtOC/aI4j3w0rN9S8teXtTB/SGm210x6vJ EjP9DU5D78CvI/zb/Lby5oekLrOk8rRjOkL2hYvG3MMapyqwI49K0phVJvyMnmTzwI0YiOW1lWVR 0IHFhX/ZAYoV/wA9PL8tl5pTVkT/AEbU41q46CaEBGX/AIAKfffFXov5VefLLX9Fg0+eULrNjGsc 0TGhlRBRZU/m2HxeB+jFLO8CpD5y84aZ5X0iS9u3Vrggi0tK/HLJ2AHXiP2j2xV8uTzXmpajJM9Z ry9mZ2oKs8srVNB4ljhQ+ndM0Q6J+X66W1PUtrCQTU6eqyM8lP8AZscCXy1hQ+vNE/44un/8w0P/ ACbGBKNxV5p+f3/KHWf/AG0Y/wDkxNhCvM/ye/8AJjaR/wBHH/ULLih7X+a3/kvtY/4xx/8AJ5MA S+e/Jf8AymOg/wDbRtP+T6YUPrDAl5R+cf5hacmkzeXdMnW4vLohb2SMhliiBBKchtybpTsK4VeT +TNCl13zPp+nIvJJJVa4PYQoeUhP+xGKHttk/wDh/wDM25t5Phs9bXnEx2HqOeQ/5KBlHzzUwPha kjpP8fe9DkHj6EEfVj+7+yizbWrKS+0e9som4SXMEkSN0AZ1IFfbffNjmgZQIHUOl0+QQyRkeQIL wKTQNajvTYtYzfWgePpBGJJ9qDce+cwcMweGjb3o1WIx4uIcPveqweZdN8n6VpWj6sZGvPRDSiIB xGGJ+1uNgdtvDN1HURwRjCXOnlZaOeryTyY64b69WYmeARLKZFETAFXJABB6bnNhxCrdRwm6rdC6 vq9lpOmy6hdsRbwgE8BVjyIACjvUnIZcohHiPJs0+CWWYhHmWDebrj/GXlWO/wBFjlkNlOfXtSP3 n2N6KpblTkOmazVS8fHxQ6Hk7zQQ/J5zDKQOIbHow3yl5d1e/wBdtBFBJHHBMkk07KVVFRgx3I67 bDMDTYJSmKHV3Ov1ePHilZG42He92kkSONpJGCxoCzsdgABUk50pNbvCgEmgwH8vhJq3mLWfM0in 05WMFty/lJBp81RUGazQ3PJLI77tUjFhx4BzG5/Hvt6Bm0dAgNe0e11rR7vS7raG7jMbMNypO6sP dWAIxV8w+ZfKmveVdT9G9jePg9bW9jqI5OJqrRv496dRhQndn+cvn62gWE3qThRQPNEjPQeLACvz OKpFr3mnzL5nu4jqVzJdyA8be3RQFBP8kaACp8aVxV7H+Tv5fXugwzaxqsfo6jdoIobc/aihJDHn 4M5A27U8dsUs280eWdN8yaPLpmoKfTf4opV+3HIPsuvuK/SNsCvnHzP5J8zeUb7nPG4gR622pwch Gf5SHG6N7HfChVh/NPz/ABQGBdZlKEAVdY3fb/LZS/44qkU1xrOt6gGlefUb+Y8V5F5pW8ABufoG KvZfys/KeXTJotd1+MC+T4rKyND6Rp/eSduf8o/Z+fRS9K1v/ji6h/zDTf8AJs4FfIeFCYr5k8xI oRNUu1VQAqieUAAdAByxVmn5Q63rV157soLq/uZ4WjnLRSzSOppExFVYkYqzn8/v+UOs/wDtox/8 mJsQl5n+T3/kxtI/6OP+oWXFD2v81v8AyX2sf8Y4/wDk8mAJfMaO6OroxV1IZWU0II3BBGFCJk1X VJEKSXk7o2zK0jkEe4JxVNNC8i+a9clVbDTpTGxobmVTHCPGsj0H0DfFXvn5efl3ZeUrNnZxc6tc LS5ugCFC1r6cYPRa/SfuACVb8wfLcur6UtzZgjUtPJltiv2mHVkFO+1V9xmFrtPxxsfVF2nZWsGL Jwy+iexV/JXmqHXtLUyELqNuAl3F0NRtzA8G/A7ZLSakZY/0hzYdo6E4J7fQeX6mRZluuSfWvKmg 6zcwXGo2/qzQ/CjcmWq7twPEio75j5tNDIQZBzNNrsuGJEDQLyv8zNQvZ/NFxaTMy21oES2g6Kql AxYDpVq9fozS6+ZOQg8g9T2NijHAJD6pcz8U5/K/lq1lqeiagDcaXwRxGxNEYsdlINRWldvDL+z/ AFiUJbxcPtr91KGWG02f6fo9loOkzQaVbn4FeVYySzSS8e5Pc8QM2kMQxQIiHQZdRLPkByHy9wSD 8v8AzP5h1m4vo9UgCxw0KSqhj4sSQY9+v6x3zF0WoyZCeIOf2rosOEROM7nzv4qH5g6/PcSR+VtI /e6hfEJc8T9hD+wT25dW8F+eR12cn91D6i2dlaURBz5NoR5fj7vNlXl/RoNG0i30+HcQr+8f+dzu 7fSczsGIY4CIdVqtQc2QzPVMMtcd2KqdxbW1zC0FzEk8L7PFIodSPdWqMVSCb8ufIsrl20S1BPZE 4D/gVoMVTHS/LXl/Sm5abpttaPShkiiRXI92A5fjiqZYq7FWnRHQo6hkYUZWFQQexBxVIbnyB5Ku ZfVl0W0L1qSsSpU+4WlcVTLTdD0bS1K6bYwWYIo3oRrGSPcqATiqNxVxAIIIqD1GKqH1Gy/5Z4v+ AX+mKu+o2X/LPF/wC/0xVdHa2sbBo4URh0ZVAP4DFV8kUUq8ZUV1BqAwBFfpxVYlpaxsHSFEYdGV QD94GKqjojqVdQynqpFQfvxVR+o2X/LPF/wC/wBMVXJaWsbB0hRGHRlUA/eBiqrirsVdirBPNHlL U7HUj5j8sHheirXVmo2kB+0VXvy/aXv1G+azUaWUZeJj59zvdFr4Th4Of6eh7vx3sbf82/Mq3ZY2 9usSmjW5Rq7dasWrXMQ9p5L5B2Q7Bw8POV96e+Y9A1TzkNK1rSbhYbVogPSlZlMThiWccQant9GZ OfDLUcM4nanB0mqho+PFkFyvp1ZNrXkzQ9aETahGz3MShPrKHhIwH81NjmZl0kMlcXPvdZpu0MuG +A7Hp0RujaFpejWv1bT4RFGTyc1JZm8WY7nLMOGOMVENOo1M80uKZtL/ADp5pHl3ShcpGJrqZ/Tt 42+zWlSzU3oB4ZVq9T4Ub6lv7O0X5jJwk1Ec2AWP5k+dNQd7G1hinurkcYDHGQ8ZPcb8dh/Nmrhr 80vSNyXf5ex9NjHHIkRHPfn+PJmvkvyYuiI97ev9Z1i53nmPxcK7lVY7mp+0e+bHSaTw95byLpe0 e0fGPDHbHHkGU5murdiqjekiyuCNiI3of9icVeB6fqmnw6Hocmkavdw+cLidFmV5pRbFTIwPqmUi LjxpsCflhQ9r84u6eUdcdGKuun3TKymhBELEEEYEoXQdRFn+X+nalPykFtpMNzKSas3C2Dtue5pi qS6T5Nl8w6dBrXmDUr176/jW4igtp2ghtkkAeNIkSm6qaFjWpwqi/Jeoanbazq/lbUrpr+TSvSls r2T+9e3mWoWQ0FWTb4u9cCpN54mtIvNyf4onvoPLclsi2E1q8qW6XPI8zMYvi59OPthVm3lqG3h0 S2S21GTVbehMN9K6yu6FiVq6gcuI+GuBWIaPplx55e71jVb+5j0lbiW30zTbWVoY/Thbh6spSjOz MD8sKst8uaE2iWclmL64voTIXtzdN6jxIQB6YfqQCCRXAqS+WZpn/MLznE0jNHF+jPTQklV5WzE8 R2riqQ/mLLpv+OtDg1ae4i0p7WczrbGfkWFeHw29XPxU7YUMs8lQ+XU06ZtCkuJLVpiJGuvrHP1A q1oLkK9KEdNsCWGeYtU1/TPzH1DVLBnuLLTbS3k1HTwSQ9s+0jItac02b/PcoT2XVIr78xPL89lc GWwutMuJo+LHg4JBBK+Pz6YpRnnnUtV+taP5e0qc2d5rk0qPeru8UFunqTFAf2yp2OBXWX5e2the 2t7Y6tqMdxDIrXJluGmW5QGrJKr/AA/F7dMVUPzcmeHyTcukjxH1rcM8ZKtxMyg0K79MIVR8n2/k QawG0Sa+kvVjY8bn68I+Gwb/AHoVUrv88VWfmZLJDdaRLfteDyuGmGrGxLqwei+iZTHRvTBr0/pi FTnyPBo6aVJLo2qzapps0haD1pTL6PwisQLAOu+/Ft98CsixV2Kse8xeRtB1zlLNF6F4RtdQ0Vif 8sdG+nf3zEz6OGTc7HvdhpO08uDYG49xY7D5a/MTy+gi0a+ivrJK+nbSUUgE1+zJsv8AsXzEGn1G LaBsfjvdjLWaPUG8sTGXf/Z+pV/xZ+Y8I43Hl1ZGG1Ylcj/hWfJfmdQOcGP5HRy5ZfnX7Hf4i/M6 8+C10OO25f7slBBHv+8dR+GPj6mXKNL+U0MN5ZCfd+wKJ8headdlSXzPqgESElLeEBiK9aUCop96 HI/ksuQ3kky/lTBgFYIb95/F/czLRPLmj6JB6Wn24jLf3kp+KR/9Zjv9HTNhh08MYqIdPqdXkzG5 m/uTLLnGdirsVUrqNpLWaNRVnRlUe5BGKvLI/Lfn+48jweTZNFtoIgAkmpzXSSBR6vqcliRSQRWn U4UM/wBW0m6k8m3mkQMbi6fTpbSJ3IBkkMBjUknYcmwJX6FpTReU9P0nUIxyjsIbS7irUVWERyLU fT0xVjlnF+Yfly0GkWOn2+u2FuPT068e4FvLHEPsJMjCjcBt8JG1MKph5K8s6pp02oaxrk6T65q7 o9z6VfSijjFI4kr/AC16/wC2QrtcuvPFvqNxHaaRa63o9yirDCZkt5Ijxo/q+qGWRSfDFVbyB5dv dA8uRWF66NcGSSZooqmKL1W5enHX9lf11xVKY9K84eVr69/QFlFrOiXszXKWDzC2mt5ZDV1SR6oU J3/z3Ksj8uSeZZbSWbX4oLe4kkJgtbcl/Ti4gBXc7M1anbAqB0LRdQtPOXmfU54wtnqf1H6m4YEt 9XgKSVUGoox74qlnm7SvNA846Tr2i6fHfrY280UkUkyQjlLUdW36HwwqyHy7e+Y7uGZtb02PTZVY CFI5lnDrTckr03wKgLLQ7+Pz7qurSxj9H3dlBBE/JSWdD8QK9cKpHo3kDUdF/MCK+syG8uJDObeI sK27zmrRKp34ctxTxxVP/OPlu81aKyvNMuFtdZ0qb6xYTSAmMkijxuB+y42OBUHZan+ZV3eWtvc6 NaabbpIpvr1rgTiSMGrCGJPiUt0HPFUR+Y2i6nrHlaax02ITXZlhkSNmVARHIrH4mIHQYqv0PVfO 1zfrFq+hw2FmVYtcR3STMGH2RwA74qqeYrrzjaXkFxo1jBqlhwZLmxaUQTlyah0kf4KAbUP+0qg/ Inl/U9NfVr/UIIrGTVrgTppluweOBVXj9oUUs37VBTFX/9k= xmp.iid:49dd06fe-db24-ae4b-8e6c-687a597063ef xmp.did:49dd06fe-db24-ae4b-8e6c-687a597063ef uuid:5D20892493BFDB11914A8590D31508C8 default uuid:15fbc65d-c81e-4071-8157-e4058c6ce6eb xmp.did:851f1798-f804-a04d-9ddf-fa25d1c4087a uuid:5D20892493BFDB11914A8590D31508C8 default saved xmp.iid:8db8b759-5dae-2647-b2c6-2b696cbd2a60 2023-01-26T04:27:30+05:30 Adobe Illustrator 26.5 (Windows) / saved xmp.iid:49dd06fe-db24-ae4b-8e6c-687a597063ef 2023-01-26T04:32:05+05:30 Adobe Illustrator 26.5 (Windows) / Print Adobe Illustrator False False 1 612.000000 792.000000 Points Cyan Magenta Yellow Black Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 CMYK Red CMYK PROCESS 0.000000 100.000000 100.000000 0.000000 CMYK Yellow CMYK PROCESS 0.000000 0.000000 100.000000 0.000000 CMYK Green CMYK PROCESS 100.000000 0.000000 100.000000 0.000000 CMYK Cyan CMYK PROCESS 100.000000 0.000000 0.000000 0.000000 CMYK Blue CMYK PROCESS 100.000000 100.000000 0.000000 0.000000 CMYK Magenta CMYK PROCESS 0.000000 100.000000 0.000000 0.000000 C=15 M=100 Y=90 K=10 CMYK PROCESS 15.000000 100.000000 90.000000 10.000000 C=0 M=90 Y=85 K=0 CMYK PROCESS 0.000000 90.000000 85.000000 0.000000 C=0 M=80 Y=95 K=0 CMYK PROCESS 0.000000 80.000000 95.000000 0.000000 C=0 M=50 Y=100 K=0 CMYK PROCESS 0.000000 50.000000 100.000000 0.000000 C=0 M=35 Y=85 K=0 CMYK PROCESS 0.000000 35.000000 85.000000 0.000000 C=5 M=0 Y=90 K=0 CMYK PROCESS 5.000000 0.000000 90.000000 0.000000 C=20 M=0 Y=100 K=0 CMYK PROCESS 20.000000 0.000000 100.000000 0.000000 C=50 M=0 Y=100 K=0 CMYK PROCESS 50.000000 0.000000 100.000000 0.000000 C=75 M=0 Y=100 K=0 CMYK PROCESS 75.000000 0.000000 100.000000 0.000000 C=85 M=10 Y=100 K=10 CMYK PROCESS 85.000000 10.000000 100.000000 10.000000 C=90 M=30 Y=95 K=30 CMYK PROCESS 90.000000 30.000000 95.000000 30.000000 C=75 M=0 Y=75 K=0 CMYK PROCESS 75.000000 0.000000 75.000000 0.000000 C=80 M=10 Y=45 K=0 CMYK PROCESS 80.000000 10.000000 45.000000 0.000000 C=70 M=15 Y=0 K=0 CMYK PROCESS 70.000000 15.000000 0.000000 0.000000 C=85 M=50 Y=0 K=0 CMYK PROCESS 85.000000 50.000000 0.000000 0.000000 C=100 M=95 Y=5 K=0 CMYK PROCESS 100.000000 95.000000 5.000000 0.000000 C=100 M=100 Y=25 K=25 CMYK PROCESS 100.000000 100.000000 25.000000 25.000000 C=75 M=100 Y=0 K=0 CMYK PROCESS 75.000000 100.000000 0.000000 0.000000 C=50 M=100 Y=0 K=0 CMYK PROCESS 50.000000 100.000000 0.000000 0.000000 C=35 M=100 Y=35 K=10 CMYK PROCESS 35.000000 100.000000 35.000000 10.000000 C=10 M=100 Y=50 K=0 CMYK PROCESS 10.000000 100.000000 50.000000 0.000000 C=0 M=95 Y=20 K=0 CMYK PROCESS 0.000000 95.000000 20.000000 0.000000 C=25 M=25 Y=40 K=0 CMYK PROCESS 25.000000 25.000000 40.000000 0.000000 C=40 M=45 Y=50 K=5 CMYK PROCESS 40.000000 45.000000 50.000000 5.000000 C=50 M=50 Y=60 K=25 CMYK PROCESS 50.000000 50.000000 60.000000 25.000000 C=55 M=60 Y=65 K=40 CMYK PROCESS 55.000000 60.000000 65.000000 40.000000 C=25 M=40 Y=65 K=0 CMYK PROCESS 25.000000 40.000000 65.000000 0.000000 C=30 M=50 Y=75 K=10 CMYK PROCESS 30.000000 50.000000 75.000000 10.000000 C=35 M=60 Y=80 K=25 CMYK PROCESS 35.000000 60.000000 80.000000 25.000000 C=40 M=65 Y=90 K=35 CMYK PROCESS 40.000000 65.000000 90.000000 35.000000 C=40 M=70 Y=100 K=50 CMYK PROCESS 40.000000 70.000000 100.000000 50.000000 C=50 M=70 Y=80 K=70 CMYK PROCESS 50.000000 70.000000 80.000000 70.000000 Grays 1 C=0 M=0 Y=0 K=100 CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 C=0 M=0 Y=0 K=90 CMYK PROCESS 0.000000 0.000000 0.000000 89.999400 C=0 M=0 Y=0 K=80 CMYK PROCESS 0.000000 0.000000 0.000000 79.998800 C=0 M=0 Y=0 K=70 CMYK PROCESS 0.000000 0.000000 0.000000 69.999700 C=0 M=0 Y=0 K=60 CMYK PROCESS 0.000000 0.000000 0.000000 59.999100 C=0 M=0 Y=0 K=50 CMYK PROCESS 0.000000 0.000000 0.000000 50.000000 C=0 M=0 Y=0 K=40 CMYK PROCESS 0.000000 0.000000 0.000000 39.999400 C=0 M=0 Y=0 K=30 CMYK PROCESS 0.000000 0.000000 0.000000 29.998800 C=0 M=0 Y=0 K=20 CMYK PROCESS 0.000000 0.000000 0.000000 19.999700 C=0 M=0 Y=0 K=10 CMYK PROCESS 0.000000 0.000000 0.000000 9.999100 C=0 M=0 Y=0 K=5 CMYK PROCESS 0.000000 0.000000 0.000000 4.998800 Brights 1 C=0 M=100 Y=100 K=0 CMYK PROCESS 0.000000 100.000000 100.000000 0.000000 C=0 M=75 Y=100 K=0 CMYK PROCESS 0.000000 75.000000 100.000000 0.000000 C=0 M=10 Y=95 K=0 CMYK PROCESS 0.000000 10.000000 95.000000 0.000000 C=85 M=10 Y=100 K=0 CMYK PROCESS 85.000000 10.000000 100.000000 0.000000 C=100 M=90 Y=0 K=0 CMYK PROCESS 100.000000 90.000000 0.000000 0.000000 C=60 M=90 Y=0 K=0 CMYK PROCESS 60.000000 90.000000 0.003100 0.003100 Adobe PDF library 16.07 ��C��C��Y"��   ��Q   !"1 #68w�$257tuvx�3AQRWXq��������%'BFabe�s�� ��D !1AQq"2a�����#���45Brs$%3R��t����� ?�� (�EA{ϲ���)������)�W [8��XVךr�xFV�ky2��J GV�N��Fs�jM[aґ����2��F�c?Xl�W��7Sk��R��,#.Dq���=&-��� �˟:�(m�i���[����5p���j��T�b¹�}G����K2{>��5:�ﹸ6��m�=��1�>�/Шտ����/*������� d>��^K�K��:���U�~}���5`����ct��\�^��C}9�Dz�w|7��������]�Jc�4$�lp�n�>ym�M��Ɉ�ϖ��BZ�z������jkP�i�}q���r4�;���0r,�����Ui�a�R'�?Bj��[��i|���钐���m��ne+E٥�o'���o�=�鵲��:�?hCL ��S��qs�q����26Ra�RFZӅ d��$j����R�ϕ'h:�@N�o�p�^c�B�bTwYfK̶���i��Cd �h���8���V�+�v���m뽠�.p�%��܂�3��;C iH�W�UH� [N�^�h�i7Rҙ��Az}����������D�;��Eu �$n�e)1��nv]iz�cP�,��6]�ݏs�!G�|`��[ M��G�Ljy��Ĝ��}n|P^F�u��J[��ؚ��n�>M��Q�i��u�3�����K�q��$�Å QP[}���4��oZ���>"���,wS{�%?1�.H�4��n��T3!�6��L��� �=��b��Ɨ�����8q�GG0{2 Vf*Q��E8Iґ�V�FZ+���eǎfF�<����4ܽ�h�=|RX�jِ�Hu.�����q :�LJ���>ZC�q.�GG��ͻ��jz�J4�Z�F=*\���\���TJa��X�"]�Γk�3�Hq�&�.GLsL�~���=!x��Th�J�J����{�S3C-9@�J���0P��eS����@&#�,�k�fƵ�%;qb| m��[�y��$ ���m-�JѼ�Y YKN�����o�T;%�"=�]��|�ݖ"��6�0��q'.���~s�;�R���T�%o�yre�X�M;�~ٓ����3�'������E�KW4�'8<��V�0�FJ�� P���$������o���5?�j�~�n��8���8 Kl���-�px���v˱��N4mq���7��� ��t�]�� �i��R������s�Zwg�:��1�r׬�G (�E(��p��QŠ8QG (�E(��p��QŠ8QG (�E(��p��QŠ8QG (�EA���0v�6��:��v(d�]�[���6� -�8fՏ�a��‰�u���qH�����Ny�[�"�K �̐����G*�2���Ǝ�” �RA-��\�"����y�D���/���p�q���}�>:b��T��j:R������AS�=x��#ܽ���ڻA�f�M�3��ܮȷ�5`gq�\����0�� O@��"U���a�d�uݠjlʽ�T������R$� ���5��%>�x��@yIE������1czv���n�QW��n1ռ�{� ��P�o=rq�W6����w��ov���g��v�^swz$y��_c�Ѳ� }�b~�Z!�b\�QV�ܘ��X��yG2�dg���]���[�#J�"�"A��iq�MZ�X�I��t'��򄸦��N��#ɲ�� }�Q+hBȉnB�,25޵���_��I�ۑ��T �Ų� 0����=eiB��\1��u͒ x�[ �1�Ne�H�=����dK[�S3�:��9$ɏC�eח�h�^c�{Bu+�7v�(�q�����c�]� }���qJQ/%�-jVTj}����mR9�YBt��ť�����:&1�R��=r���e �(��P�h@Bk�{�v�����]k��p��q�9C�FX�t��lq�\�����70��y����:�����}ūމ���7�'ۀ�N*�-�jJJ��Lg!�!&BP�Ya^�VFz]��$im����-�� ��Y ��n�mC��ۤ�9�B��sT58�6��%�'t�%��������):�?������� �e�,�‘��Ʈ�$��&s�̴ ���|X�D"�pT�V���6�އg6Ej��F���1r;l�����S��BKYv2FH��(c�&�bܯo�h��[���H�'K35�"k6�l��� J�@D�19~�L��]%՝�\a�������1Eż91��<� ��R�x'GSkі��P���e9��ˌ��NG[NGq�-�R��RAmM-�M�8(R IN N1Y�S2�ɐ�֟fc/:ܦe!���! R^nCn�����R]K�-+ @���j Y� =]>� 7c4�H�ޚ��lr̕�X7ь4���m�Tt#��<&��u�0�SaTQѮ�#�VXw�jKL��l�鱢�&���� .GV �m+����!�-� �G��wgZ��;B��弱;Ӎk�p ��pݺ䥆'#)C-��T���=c��������;ϐ�Z㗚��|�Qi�TA3�)m�M ���ʝ�,���� �u�V3�4�k����5���A���%jBI$3! K��!)Yh�Kmf���l�F����]v�!"�`��ʤZ�-a��X*� �9Q%kdH �� h���]G +��٫���ͮ�7[�ף�����5�記��S��y�-��������Jq�yc�9�2QH/~x��:�̄_u<��d7�7���Ԫ��iY� ��3%c��{Ym�wjF��YP�B� A�8�i�c��ݚ�i��^�`�-z_G�_��J/�3-���fܶR�/����'����|��1�i�C�*�u��OEm��������dhAm��ŷ\:K��h̼�#������ф��U}�Oi4U�غn��p���A�6��Zm&����kU��䌛�ˌ ���Qq�����9�����Ɛ�9�A�o��'� P�'AC�ӋHs�ft��o�>ۤT��ű�/NT�w)|+9�0�<�o�?��� ���P�w:)��l��"n/c.�^ `U�[~~jCRR7�h�+8��\\S�N|��/�����~ԛ��SdꇌwY�+K��v�����$tE�H3��r�(f>��1�|s�� -�&�ᏸ����-����������������;���M����"-ɶ5�����Y- ;.�6�'cr-���H �F�D�IH�w)�����$��Bp ���p�G�V��^3����?o���8�������v[gSj��<[��l�wJ� ¼ZOv!��j2��[�!�Pc���H�-���^K �xm,#���x9��ԉĥ������R�l�՜�%��֬SU����� \4�1�),*��YI.����[������ՙ2�Q���FW�F:u�)��Ǵ`�FD���it1�g�PI�4́�^? ���1ۉ+8��NZ�������7N:Ӓw�q�x� �^#p]��Qs:�[c�d��O��Pu�Ħ�L�4� ���y33hZ�1�p:����c(T�{<����r�i{\1H� W�O����w��4�'���+����Mj�L�Z�! �c�z:�&BS���&!������s�ʓ����O��'���*��������͹Ni� �6��m��k�o���9Bm�2s���gӳ�P�{ N�ʚKJH���pP=��M r0v �J�Z bGu�@��.��4�6�/6��ӭ�Hq JЬ�8�[N�ۅ��s�;Kݍ7�!�ytM|�7]���- ���L��$��~-��ۈ��/?�F�R}J��P�{ZmO蔩F�k �^@*[BS�Y��#���vz�$���B��v)����hM�P)v]0����0#-����ݕ.l�}W���;�0�0���"�# (���GfKL0�-�-��-!-��iJBR�� �1��ChCm�(m J��! )JR JRHb�Ӯ���<��u�V�]u�)n8��*[�-D�kZ�R��T�I$��/�fޯm�^�ђt��ՙ+#�Q ��9 w�Մ9H�"�`���=� Hː\�[-��̺�k�طɶ�6�0#Z�� 銍T�R���'So��v�J�l!��� �З�{�c�MZB᤭:�\Ǖx����5���-�m�����o*��Y��z2ې����Z.�:c�2�������_y�~����88�n���m����+)�� 6N�Z�"d�b�=��f2Mc44s�<�]��S��f�:N��#]���¹Eo��⽈�8�t�.0��R�m� �P�2P�/�ڮ�-[ �/h�i����5?9�\�.,��S�b,��̸�e���K�B�8�$��6ԹО�^:�3�lw��vp�X�q��e߉@��v%e���ur�R�8����ç~�'&z�ve�����t�r�D��暌�x }L�qNq�S찢�HChKe-�N~b��O%������O۬Vk�-/ȝ&]�ۖ�C,TC�1"( .:��J�q ~CA��Ɵ���J[�y;HR_�8fd_��9&��y�K��cur�y����L3������֥g�wg�-���*Z��Q�pG[��+\$�!-JW���䬒U�MW1�ѵ8��cc[�۷%� �4��2��%�n�eWFP�a ��#���Ԁ3�.�Z{S\�c��PU�}|l����HZԔu��f]Z����$3���#҈�ts eN �!K����f�X��[&Ɔ���;�K/"�JLt��Gi���l�� �%8���=����k�]�Q9~�O��� A+�n�gnQ���1hHD�[y�~|� �HZe��.�@@��uX�9�ӥ�mD�.{JB6�������4 �=1/ �k�!��̍��A s�� �aX�s:�P��>���n �\/N�( ��J����}�2��/u�b<$8wl����_y��U��/iz�\]�ȳih�m�U��D����rJPR��kr��]e%������2Z��k�B��l���Q�@BHHb�^��bP��\�Q�"{ϡ��B0�m�S$���6˨�y�Q�b�m�!���摢ȅ�Xm��m0��iJ y�[qjh+qiX�6�俢�)�"$��� ��㛌��;�������.R%����7��2�o�f��V���߷���wRcբ�R���T �wj��F&n�?,b����a��-��XôS�o*V��[������eG��&X��VMZȑ ��4����%#8m̷����Wa3T��׼�m�����f��+��oȓ�4��G�W�۞��$��8�)(�.s� ��(����v&���� ��s�k��q�[_O����h����#.Ɓ%d� ��ɒj ܶ��Fs� v�r�A雷����d�U��i7���׮�g�5���IY��@P�� L?�`D���刖�H��p��m�V^E�6�XW�>4�����s��Wc�_s��R�ћ�W��vV� v�OE�?��(a�EQ�ɆJ��cb�5��>Jm�y�p��������V��C�;cW�꜅B� �8�F{o �q!��I��@��? 9����|WV���h(bXf@A�Q�GZч��d���z������$����\�'' "ʒ�R�>�>q1#�-U)�8�!���|�72�Zq�� �"|;���#�C�O�o�?э��OQ�>t�t>�^z����B���h}V�m�;�1��u>'�S���*�JZ8Q^qۏ��ڟ�{��<�'OA�>U������%~au���`W#_Q��5":����C_��Y�N������o��H�g��I���c������06��l��=�]��x���a��S򎲱y�ֲP�ZmIs BՅ+�3�<� ���6����ݬ��;�V�ɥ ��K@[!y�c9J����J�匭�e8ϟ�>^\n��4����#� ���s4��J&���Hz�>#����B �%���=A��0� 2=��1�FĬh+!�-�����i��{�)��U��ں�|�蝹b*c��A�≙)o���eK��E��(ZQg:�VhU��"���h� @���5i�1��Ӓ�Þx���؟"�i3x|�@�N���i�ME*�-6d]F%�q4MD�T��=����M��il���۫k.6����ɍv�����<�� f qp��}n)��)��oiKJHI( )�eyAA��vM� -�k��Wym�w̛��j��}���܉��o2eťk�qIJ�TR�y�+�|;��źO�������v􍨸�e���kS��8|د�6|cő(A%Ƒ���9`�$4^Z�ɵ ���m=78WIN�q�?�0��YvJ�.��Y[�[���)HJ�km!�����o�7E���9�'��u��#ڙ��I��ܠ�i,Bu�bK�Jn+m�%�(Bq�3/,��Y�~�'��ܛF��� 6�h�EZ&���*�^r@)i7%�@t����ϋ��G�$�)�^|���>��:Qs/��7)��&!4�1b�[}�!收V�β��Z��$��:P�E���.�۶i�(_�b��7IwI ;\n ��Hɇ��%��cʕ�䖚q�_,!���S�Uez8QG )p�����٪�NǮ���@�Xq�d�n!ڍ�Yc[��6�� ��g�Y/'@�I��Y~9�r���g�0!Ԩ<����X��:�^�"���L[D ��u������S%��N%$�vy��� �kÞ�'�"�%+��FUI���V<>���m[��ҋ��f���.��?��P~n�����dZ�Xެ�82F&%)Ǜ���i��ƒ����O ����Dt�n֊�������)�C��u�9|���_���p����y�����!-�Nei�'�{��J��J�c�=k�łRӥ�%s_X&��_���v]o��C�P�BH�}��dy������axNV�!$�� 0@!�� ۲Y4&���km����<�I��B]o�� ��� ��U��1��c�@�}��1}����VC���P�-�ɘ�ʼ��i��RM�P��5�RY�SG�Z�� ���,��ќ$���R�N{�E��v��*T ����:|�e>�R�����ꅛf��v>��� �l�Oi�1|��F1��/0�v�����Z��ec�a�y�$�84� ��:V<�fÞԛ*��*וֹ��@[�T��\.Li �S�aM�� �U�6���è[N- ���;� pA���v�dI�!a�s.��ugpLǻ�cpMKb8G3�g8�V;��8�s�g?,�����:������ϳ���Q����ͿGF5~@�����t��VC�KG +�;q���S��x�g����<ʠWS�~u�?��.��@�?� �k�<>��GC�����k���?�ݳ�3��[��}i���*�x)~T�V��Q?�_�}�1MG�=�#[U�55S���¿����w)9V0��V�s"�P�!o���ϯ��N\�GP�~[��S���,cZФ�N? E �>5��OPV����X�I�k�P���k�D4���>�%f�+1�JȖ�:�d��a�_��e�W�c�r"���{�(P�����]�>n� ����-�QvFĮ"%��\��c�s�o���i%���™("H�-�\N~}i����������� � [��Cjh��!��4�R�ִ(�+�޸�e���4;�U��ۊ����1��q��IW$;M"Dw���M�� JH�b�I�ƨ�"� )�K85���B�l\���/��Է�ү��c?.o��A��q���V���R�XFw�A�T������ʤ�1��irk,�� 䶧Bxip��APQ��-����M{M�dhLY����j�a���Zj=�يUZ=Ŷ���J8���-�[��.��H��Ի\�j�U�ԭ0%���$&�* r������MqL��� �Ĥo-��+HV��CɳNl�P�uz��_�%ح�i�i B\�u��^ad�J!�Z� ��}-8[.Ƕ�`��V}���L{��.J ׬�"�_�L�aΒ�m��)'�\��)_�<�Ȃe��FɽL�y:��3xv2�14p��S�Y @i碥��l!��i�F7K��^ٯu4 !t�i�E�Ƥ*S1��c�)N*DX��*4gˎ�c�����q=s���QŠ�7,��S�i]a�M�M�.�XAk&}��܏C����%�%��s l��Ȏ%H{)ϑz��v~��~�� N[�)�KJ-�y:����9,%�].��b����]O ���/�o2�d5orKi����)�� K�B�h���P .� �������c{��%Q�f=�Y�� �d��kȐ��u��׌�0��C��#�e!fEm�Tl����o^S�|�� %�G�q�c���qA��)M2���[“Ih$7�!z#�KMl��L/B~�!r6�x��RYA�2ZQ"J{��Gx��&�� Y�ҦعzU|h���lP�i�n�W����3�ú�E���(a��̯%.036�0�-�,6Gnh��j����EeRӺ�Ĩy-��][�"6T�&�$�R ���qjXg�������J,W���B5����w�d��� lP�[��S� �>8�}�k��I�Γ�yz].��>xZ��z�������w�e--��o��^�_��ݪ�>����a�"i�T�Q� i�ӌc?P�q_�ǫ���˷�{~4��w|��:՚�a�o7;Q��OB�ۨ����J���e+��Q����gɂ^�zU�g�����w�����vM�u�}XI��#��Xu��Y�;`����8���M�=7/ ����+ɛ�&M)��qؖ�s�mH�g��}��&�g�����TٜB����qἬgУ��`$�j������ӌ��%aJ�0�����H����i�x>�a����F<Ҍ��z�XiIVA� �`�i���j�psP��J��aH��”�z������ꏿ���f�m:�UA����Ҏ�M�:�!��/�A��' �1{�*�7��KQS����>��s O�>xQ�x�C����lc*��g*�q�c�s��>X�1��s����|��OPV�7\ �_��X�J�%\�e�Ay�h:F�ǖ���g֗�s ����>|�sP�7֧>��?/m`k�T�Q����ͿGF5~@�����t��VC�KG +�;q���S��x�g����<ʠWS�~u�?��.��@�?� �k�<>��GC�����k���?�ݳ�3��[��}i���*�x)~T�V��Q?�_�}�1MG�=�#[U�55u;��&�F�]g�lX*�V�h�%�a 1\���-Y����+9ϖ1�������+�ի��/kY+�V(��'c硣&�q��RP&hV�e a�)9��8�3��#��?�.��?z�w�n�����v��f�Ǚ�um���%N��~&6K4鱁��Bi�G~���0*�h)X�1��͛)�Z��Med6�v��s����R���s#Iq�ʸaKB�\ �R��.(/ryDj}Ap�n��6˜�t0o��J%�6�d� �y(�)-8��)tG[����-�[S}��Ѿ����m�j�M{ ����ښ���<��ۃ���]fY���=���,�ҏ��$c��/�c�}��j�P��j� I}�G+1�FR�j}�8���i�!�Z[���ihu[�Cu�ܶ��;n�ڧɺi���Ce٩hO��Cjy0���mG��,!ףHe� �q��M�� ��Y��QŠ���(]O���. [F»="�Z"A�هH���9�̈��xA������Q��F:c��ׄ���ǵ��:�}��ې�c�24L-av S�$iq##����2��t����S�8�pP�P����:t����P�r ;>2�Y��� N1��Q���ާl6��;7m#^�=�����)0����VR� S��0����䰧�9�v������ڔO��$Ŀ�F�&)���|]�76CXW�H|k �J�#)�*BZ:3W��Dz�����ꟾ�b=o�}i����ZW~u�-�M�vN���emhVr�Һ�\QZ�Hǭң iJ}JV@��f^0���py����H�����<9���|/|BU����b�܌���%�孈��d�.�20 W����*9����"��N��`����Œ=�Ny��J�*�9�kd��jk}�V��.���VEX�U�Qd�JԄ�B����X°��$D'�� ����M�z�m�:����[/V� ub%�?'`�ˁ I�U�*FI��g� ����8�zP�+8�J+#�,>%P��, ��1zF�4���C��̴���|@HC&�O�C�=ԋC�1(�e tE�8�R�s=~U��C�Ϋ�U�{EڊH�ƺ���q{f�8�U��3�d-e��8i�nSb���� \6'��J���Tp=��"FO�u���V�{�����������ȓ�x��J������_���.����.��J�mS)׽/%!�*xZ޴1��3 !�ӌ3���6��B�'�ry������c��a?�#���7���I������ .Gx���������}ݩ�G�~��rt��P+��?:��W�P� l��r5�SR#��� ]�t5�[՟������x������v{��@� .��� =��m��k�T6 ��ۧ��p��]X�a�Y����yIdv�}+y�%�ҥ���ꟾ�j=a��V�&;��x��e;;��t)kS;n�qz1��b��'�q�H��� ��ҹq���:�ʳ�����Tݴ�~����2���4�����\.-Qb>�SU�������S,.vbLX�eap
r�*BD��^�����zF�g�韏��RJ�:Z��m�GӺ� ���Ƌa�i�E�����L�����Ŵ\����� 7R���mn'��h |��?_����u�-~)�j%F�M�x��_1���0P�:[�aJx��ꕕ8�V��9�s�2O}N9;�[�r��/ s�H�@���!5K���B �1\�t��cdhdž�\LZ��>ԞPڜB���W��kN�Y�Z53eqw�mn�AY��T�m��rW��A5�t#Gj�O�B�<�Rh9f�d��o�����44�Yn�C��;)�Zߊ��%!�c8�<��H�P����r#��ph�����Q��W+���2�m��~{.[�r[�;-�>�w㰕�� �sqM-����q���ۖ��h���~���枵ó�f�-�lYl[c�$I���[Q��̴����C2C��� �f���=L����oH j�Z�R>���ͤ�FL��˘tj�F"�8�(��`���-É�j��&ڟ��`��?�o'�p{����&ڟ��`��?�o 0{����֦ڞ�_�i�?�#�F�����[Œ��5����SמV��{=����c\_e��uu����\i֜�ɭ�q�B�Z3�!i�R�� Ns��<�=��T$�G��=���I��F*Q��p�-�v+�\�MCn�)M8�Mi�҇S��^[�V��s�|����zz�c��K����l�Z�ĺ�^�b@u���� %,�V��,��1aN��2�]�r�^Q�� �V�}�ZE�q���=՞?�6����ͱ��y%3�� r�?t��"5Е)�a-�@�C��� C"ĺ╜����9�����H�0{�®�������� .ji Q\}��2Ӹ=�K@���9^+����r߭M :˃�xKd�"\K�B����s� '�;�����H�W��R���c�o���,�4%�hK�f"������x�V0SM�H4���dr�$LHQB�ƥ}�� H=��x�uU��u�.�i;8�X M��&Fp�l�a����yg-G� �P�+�K���ˤ>1�k�*ޯӲ��q3�"]����2�%j��jB������ *m�6A�7�k�m���r��6��f�%?i����m"�jlt�%�#� ����~�3aU ЛIDC� 8۵��fs�%l5�'qѫC�î�ה�p�6��^s-�0��T�x��n�r� zf�UQ��:̃������K�+�T��&<��(�܂�qV`�A�ɝ=uk^ip���T��y0������y���a\�2ܡ���? !���%��Y��ɨX�<�~z8IxI��"e��e# ;��l9�����y�c8Z�g��2#�-���i��Ii�eԅ��.���֓�HZR�z�k�›.�2-��bM�!�q%0�����q.��N$�!ƜBV����T_ij]Ӟ����[�,ӭeU�C���MML���zOB~FXч��(|�B2�`�@�� s8���c��!���+r`N\"�HC�$HN��d:�����D6�rChJ�hR8����Kj�A�-�h >�/k��Z����v<(P��iR w#@�����o��)�w����2�A��[ǔQ�IA�>�ž[�e�Ix���!ה�\ykS�qYZ��g9�1S�[�ukZ�ZˋqJ*qKQ*RԲJ��(�I$�s_Re�ZC 4�L6�Zm�Д4�HHBCim()BR����1���V�?Nu"�%YU��2�!C�IHL��4��rM��.��x�U���2�ZL�I%�.�_��d-}�lGWC�Mq���y/:�RV��]���K��*i���.!L� ^������c�b��f�1`fsV��A��-�> y�FTlH���%�%DHa*�ܢ�r�$�V����mlV����u���*�J��CY1Ė ��3!!���z}R��|N~%r���w�3����E�B��撵 ����'q$�綾E����]sz� !:�_ZF�����5�w�6��ܹ-4��G���l�XR�b'��i�����]��}��ّ{Ppfb+bE���#�F�l �eur~�i� �DFO*k#6Y0��P�b��6�Ժ���7�7"ge�CwJ�[k+y��xK�P���܈���BR�4�O���/h��;�a���L���5Z�O�7hK�)NJC���Z�ӯ��s�R���F��s���1j�$)Iu� u�}YQR��+�>�d-.:ӓf���C9��ٮ�:KO��?��3n�$)Hp��!�����Ag*K�V�-8�{u�Rv���v޳�5aC��<� ��V<�� n�͡M��)0��ۈK��U���T�(���O�+֨ס�0�Hr|�"*~,�����c�E�w� �1�i^X�q��<(�)]:�2�T����E�z�Z���Q _���)��r�������ן����'��M&p� ����&;�ڵr��ai��BF@�%xǧ �QB�6��\+ y�/?.%.�+����QŠ����#oTʥ�9��-�l��X�FW�ay@���r�cVR�2�cϟ�8Q]����nV����^Q�0�RU�]G�=�S�4�ّ�c�1�c8Z\±�y�>|\��8��&p�T�ĥ��p��QŠ8QG (�E(��p��QŠ8QG (�E->�t��o���K�&���*b�=���d^��g�c���A���XTv#�GX��96P6yP�AL�-�]��0�M���%��CI�N ��;K@���-�c?��֕���-��t��m��6z0�$%o��W���{��Ēc�"�0y�L-N���~/���v&WF6�ԉp���f�̓�N9߆wA|�b�R��͏�$eB�� ��%^�\S�w�#_�a7� ٺ �:i[����Z�%ƞZ|�`���-8�Hv���\���KҲ�ܛ� ��]�!����>��]N��/q&b!���c>���\m��”����q��f�B��Dm�٥;-RNߍ�X�ז�ơ٨_f���jd�Kbt��rBY ŕ��K�������>9��F�t/�궥 T�S0.r/�qN&S�l��K+aJi��J�#P�)�<�5��.�HI������\���0�l�(m���a��!\����BBܷ��ϛ�@K��� �o\���"6���1t�&���r���h�“<�Vq���㉔�YV.�=��;��$��)2n��S�CnnC��<$>�뒖Â�����8P���[m!�@�� 7&��x)�� Rd����˰ٚ��Ϧ������NP�YV�W��J�R$H*�v8X�X�Q� ���e�R��������8���!�_u�oB��<,"4H����60��ln�#$�q�JQ*R�R�Q$櫥��{�ͻ]e�:�q�칲�V���yEKZ�R2p�!)m����R�[�k�JwT)���qd��6�L �Q ���(�{L;$|�����xĖe�g�Nq�s��ܖ��4E��2\ɳ�p 6�h����<������[akKn���Ж�R��'d�&�m^�* )M��v��~�wy�HLT�R��.\n+;�W?)�[RL֡˪��(����F��i^�S��r��`��c����e�%Ri���~M�����#����M;" b4�hq���q��yg���ϕ5]���Ůj�k߫B�_5��A��ص��!�)��hh�����>N0����Y������)�����t��P)��ݔ� \�V�m��!�Ƅ�E�1*B�'֦A ��R}YN�ǟ�֗�. �� ۺ�6�ܽ��:`Njl֚S��Hmz��4�O���n.�;9x��¾ �� Ltdd�/Ɗc3�^C�2GRs����Jn �H���=k�i����'fbz��� ;���i6 �]��l|U��Rԇ.z�`������7=j`Q�4$�'��� N��s�;;NE ��r=�,|;:��#;���t�"Z�j���7-߭����0��JjWg~M6��pD�"#���ТIbAza*�����>�@=��P�����8y����G7X��������vj����lU-��V����%Cg@�Lx��Q�:�<2_-�0����B}�#�����_}��k�w+Z�^����!#l��slZΙӐ�ku0 �m�-i�Yr>pBk���$&$��P�\`0�xfKY g�A���u=>�nuc��TN-�x�vW����I4�ztBg=>��}�����FET�]Xߌ�p���]��H�����8��s�gûٜS�b`X8a�2�O����!f4))�Ce�9���9S K�I#"������qM�U��ط��J�i��\մ��q��.��\5؊�|��p��T�s�"��C� Ty6�_�[U wV�:Ws�ŧ�{%��骮��k�[�h;^8D�o ��f-1s0)q�P�p���y��[�����R=p �h�w�H���;���U��"�R�Њ�lv�h��}���v�h1Kp?�V�!�I�W� ��%��H����`r*X�de��{@�a'���w����}J����YnD֯w}�ra�GM����5��}�.�jeYKD̾#�Jl��R�$F�D���<��wN`r��+<��=�z� �[��۞{�}�� �}~��+�S��!�.Z�k���:��� b�)��G�W��~>S0٨m P��z3���㰁ήv������-a�8�9��K�fe��uO�!')O�8��y_Y�K)�_}�}gqk��\���G (�ES��t�Mvi�e'Ar��� ���l0ܫ�i�DZ�@v`�[BPnY�������-� ��.8�L�Ji�G�X�so���O��*�b���������Y�<�FS��y|�� ��M��>���+{�!?�c�\��]��^����s�(��wʍ,�-�A��;]�����_V[O�����|��[#2^���n�򰟞0�}Nx�6��RxV�U��%G 7�f+N(�� �ȑ�y`DW�'�t��$�n���P�}=���s*��(��؏�Gj�(�$uT�v��7�}ʩf���J�lt1���f>P�L)�@�N,S�;���2c���o! !�YJ�F8�͋_mV|)��L��t6�j;���* <���-����q[�����a@$)i,Z�cWlw���u�[�|�s{�>̉�Yۉ% ����mȌM�.+�܋��hR�[ie*Ac�`���rIJ)����x�߽�6[j!�'��ޔH�>�y���"Fsз�D�b>���tn�,H�,��o �#)����=/1���6zqT���x҅�Vs�~�u���Ф��2�r[�Z�1��O)m��<�n4�)Q�iz�W,����E(���|V�ׂ��i �i��?�q%�6&���Bf��b_2�K� �ǁ�=X|d�N]N}iyϗ��^9����ï���<����'��m����:Ԯ��k�eƉ�I���o���&b�k��I(��ʌ�~Hyy�V�Q� �w�>΄����T�����,c���Ϧj���2���6�N<�n�w8m�)�� �UL�8J1�g�3���cy�q��ӕ��>b��ՠ��u~�����fȡ[�R%��8�����5��i��[�� 㭧֏RМz����G"u)���Ū���:�C�h���7�v֫�GR����\g(b� 0��[Z�ˁ`� 3Ί!ұ����vV�mH�N?x���y|���ֺ���Y{��zjk��MG��j�^뚖�s�2�+�o�29u�-�� z1���{L�=_\�O������1�g��9�����HNq�ds�^]��x�?���� 1��6�~���;U�sЕ ^+T*��g;������e�cC���%o&+���� �Px���'_g��'\ѣ%;�E�xx"I�~����lS���32��g�R$4d���~E��":�3 _C�(�v���8;�yc�9�>���dn���ׯ��>�_ ^��j��s�j���a[�mN��������!"�`�B�#o��B���'5&����+}��lP�Mk��d��1��m9Y�Ga�;����j׋GQU ���٢m�N_^�ԗ�nLZ�ߞ)��" 0n̩�����br�,.A����t����|h �z`��}zS�L?a�W�Ɇ��9 0Ezu����~H vdv]}�%b�}@Ȳ��4�l<��q ���Z\�m:���u�������eM��ץi±�� �ϥX�N|�������G֚����*����t#�]E�vv*�+���{�y�m����_�L�2<��#�v��}2�B��w��AJq������t��=��5X���ޮ�O�F�C׸��FP�����J&���̐��*5|�/�(4���o,K4/���B���d���1��2sN'8Ƿ�*&��.��o E�ӎ!��yS�B�����Ⓦ� �~Xʳ�g?������S�>?CU���Q޴}?o�% ����&���]��Q�ZY�X.F�7� l���+s�W��a�D�I�K:�T��z���`�;�o暡��9s�~ ���|i��� �[:���X^4v�°�g ¾��=XV�±�<+��>~>!�|M>�����^��:����%7N�c�.}{�a��M{=M��g�"�un:X� �rbL�Jl��1�>�?aG�tґ�c� G��Ο&�r�A�y�q��W��}��=�����c/S�J��9km�S�+Z��2y�!^��cb.^^F�F"Q�öm��[%iS+!#�( ��×��}Q�ɭ[Z�]���"du.��~�]� py�7�J�B��26KX߱�=Yss g �Irs�ז9㷝"��=3�5`:���;���T�F�����D���7_���*qS����kK M�e�b��VdI+.� L�[�! �ϼ��@)'�3ᏥH�����B��=���SzOd�5h��CM�T�d@\c���8afN �&I)qG=T{d�+.:���@ ��{p~�zR@��� ��Z��ܒ=.M�����bܴ����^싷ԏ�{V��s9��H�b � �P"��X�2Ҝ�g��Gy�����=����|i����8QG (�E(��߯Ȑ��������w�{_�s�+@l�����&�Do势����y����?Z�V��*�!Z&����+��?�7�[�����H|��w�/�����ɦwˎ�-(��p��QŠ8QG (�E(��y��G����Q]�?f?ɏ�p��}��&�Š������ƑŠ�(���ˆ����� +����QŠ8QG (�E(� ��=1���3Š���r"�����o��p��W�%���"��9Š�+?������� A�ޯ��s�-��
    Get the next $SLDB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLDB

    DatePrice TargetRatingAnalyst
    1/8/2025$16.00Buy
    Truist
    12/13/2024$16.00Outperform
    Wedbush
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    7/15/2024$10.00 → $15.00Neutral → Overweight
    JP Morgan
    6/24/2024$12.00Market Perform → Outperform
    Leerink Partners
    5/31/2024$20.00Overweight
    Piper Sandler
    3/28/2024$40.00Outperform
    William Blair
    3/15/2024$16.00Buy
    Citigroup
    More analyst ratings

    $SLDB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Solid Biosciences Inc.

      DEFA14A - Solid Biosciences Inc. (0001707502) (Filer)

      4/25/25 4:03:30 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Solid Biosciences Inc.

      DEF 14A - Solid Biosciences Inc. (0001707502) (Filer)

      4/25/25 4:01:30 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Solid Biosciences Inc.

      PRE 14A - Solid Biosciences Inc. (0001707502) (Filer)

      4/11/25 5:03:57 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units ("RSUs") to seven newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducemen

      5/1/25 4:00:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences to Participate at The Citizens Life Sciences Conference

      CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with management during the conference may reach out to thei

      4/30/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

      CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 2025, in New Orleans, LA. "The data we will present at this year's ASGCT Annual Meeting reflect Solid's significant advances in next-generation capsid design and therapeutic approach for Duchenne, in

      4/29/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 4:17:42 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

      SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 7:59:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Solid Biosciences Inc.

      SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 12:02:53 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

      SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 8:56:19 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Ian F converted options into 4,574 shares, increasing direct ownership by 4% to 117,546 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      4/8/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Solid Biosciences with a new price target

      Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

      1/8/25 8:30:04 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Solid Biosciences with a new price target

      Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00

      12/13/24 8:18:51 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Solid Biosciences with a new price target

      JMP Securities initiated coverage of Solid Biosciences with a rating of Mkt Outperform and set a new price target of $15.00

      12/10/24 8:02:56 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Financials

    Live finance-specific insights

    See more

    $SLDB
    Leadership Updates

    Live Leadership Updates

    See more
    • Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

      — Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants

      2/18/25 6:45:43 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

      - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a

      1/7/25 4:15:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

      - Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance - - Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 - CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financ

      3/23/23 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Solid Biosciences Provides Third Quarter Business Update and Financial Results

      – IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme

      11/8/23 4:17:49 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

      - Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. "We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duc

      10/2/23 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care